- Home
- OPBK vs CRVS Comparison
OPBK vs CRVS Comparison
Compare OPBK & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPBK
- CRVS
- Stock Information
- Founded
- OPBK 2005
- CRVS 2014
- Country
- OPBK United States
- CRVS United States
- Employees
- OPBK N/A
- CRVS N/A
- Industry
- OPBK Major Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- OPBK Finance
- CRVS Health Care
- Exchange
- OPBK Nasdaq
- CRVS Nasdaq
- Market Cap
- OPBK 213.7M
- CRVS 206.5M
- IPO Year
- OPBK 2018
- CRVS 2016
- Fundamental
- Price
- OPBK $12.88
- CRVS $4.43
- Analyst Decision
- OPBK Hold
- CRVS Strong Buy
- Analyst Count
- OPBK 1
- CRVS 3
- Target Price
- OPBK $18.00
- CRVS $16.33
- AVG Volume (30 Days)
- OPBK 59.7K
- CRVS 1.4M
- Earning Date
- OPBK 04-24-2025
- CRVS 05-08-2025
- Dividend Yield
- OPBK 3.81%
- CRVS N/A
- EPS Growth
- OPBK 0.81
- CRVS N/A
- EPS
- OPBK 1.42
- CRVS N/A
- Revenue
- OPBK $81,356,000.00
- CRVS N/A
- Revenue This Year
- OPBK $16.57
- CRVS N/A
- Revenue Next Year
- OPBK $11.98
- CRVS N/A
- P/E Ratio
- OPBK $9.03
- CRVS N/A
- Revenue Growth
- OPBK 4.15
- CRVS N/A
- 52 Week Low
- OPBK $9.28
- CRVS $1.75
- 52 Week High
- OPBK $18.57
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- OPBK 58.77
- CRVS 68.59
- Support Level
- OPBK $12.50
- CRVS $3.17
- Resistance Level
- OPBK $13.06
- CRVS $3.71
- Average True Range (ATR)
- OPBK 0.46
- CRVS 0.23
- MACD
- OPBK 0.10
- CRVS 0.08
- Stochastic Oscillator
- OPBK 83.80
- CRVS 95.47
About OPBK OP Bancorp
OP Bancorp is engaged in the general commercial banking business in Los Angeles, Orange, and Santa Clara Counties, California, Carrollton, Texas, and Las Vegas, Nevada. The Bank is focused on serving the banking needs of small- and medium-sized businesses, professionals, and residents with a particular emphasis on Korean and other ethnic minority communities. It operates with eleven full branches.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).